Licensing and Commercialization Agreement with Novartis Pharma AG (Tables)

12 Months Ended

Dec. 31, 2016

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of collaboration revenue components

Below is a summary of the components of the Company's collaboration revenue for the years ended December 31, 2016, 2015, and 2014:

	Years ended December 31,
	2016		2015		2014
License revenue	$	22,937	$	38,083	$	38,373
Research and development activity revenue	9,741		8,378		2,000
API transfer revenue	18,212		5,020		883
Joint operating committee revenue	19		24		3
Total collaboration revenue	$	50,909	$	51,505	$	41,259